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Recent computational advancements in the simulation of biochemical processes allow
investigating the mechanisms involved in protein regulation with realistic physics-based
models, at an atomistic level of resolution. These techniques allowed us to design a drug
discovery approach, named Pharmacological Protein Inactivation by Folding Intermediate
Targeting (PPI-FIT), based on the rationale of negatively regulating protein levels by targeting
folding intermediates. Here, PPI-FIT was tested for the first time on the cellular prion protein
(PrP), a cell surface glycoprotein playing a key role in fatal and transmissible neurodegen-
erative pathologies known as prion diseases. We predicted the all-atom structure of an
intermediate appearing along the folding pathway of PrP and identified four different small
molecule ligands for this conformer, all capable of selectively lowering the load of the protein
by promoting its degradation. Our data support the notion that the level of target proteins
could be modulated by acting on their folding pathways, implying a previously unappreciated
role for folding intermediates in the biological regulation of protein expression.
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P rotein expression and function in eukaryotic cells aretightly harmonized processes modulated by the combina-tion of different layers of regulation. These may occur at
the level of gene transcription, processing, stability, and transla-
tion of the mRNA as well as by assembly, post-translational
modifications, sorting, recycling, and degradation of the corre-
sponding polypeptide1. In addition, the expression of a small
subset of proteins is known to be regulated by the presence of
specific ligands, which are required along the folding pathway to
reach the native, functional state2. Typical examples include
nuclear receptors, such as estrogen and androgen receptors3. The
integration between these pathways and the protein quality
control machinery, deputed to avoid the production and accu-
mulation of aberrantly folded proteins, is known as
proteostasis1,4. Mechanisms by which proteostasis is ensured
include chaperone-assisted protein folding as well as re-routing
and degradation of misfolded protein conformers. Consistently, a
large percentage of human pathologies are linked to alterations of
proteostasis, including a broad spectrum of age-related brain
disorders, known as neurodegenerative diseases, characterized by
the accumulation of aberrantly folded proteins in the central
nervous system5,6. These range from highly frequent disorders,
such as Alzheimer’s and Parkinson’s diseases, to rather rare
conditions such as amyotrophic lateral sclerosis and prion dis-
eases. The latter, also known as transmissible spongiform ence-
phalopathies, are caused by the conformational conversion of a
cell surface glycoprotein, named the cellular prion protein (PrP),
into an aggregated, pathogenic form (called PrP scrapie, or PrPSc)
capable of propagating like an infectious agent (prion) by tem-
plating the structural conversion of its physiological
counterpart7,8. Growing evidence indicate that prions exemplify a
mechanism of protein-based propagation of information exerted
by many other amyloids in pathological and physiological
contexts9,10. Unfortunately, the absence of detailed information
regarding misfolding processes, as well as ineffective clearance by
the proteostasis machinery, have so far hampered the develop-
ment of therapies for the vast majority of neurodegenerative
disorders. Fundamental insights into the regulation of protein
expression, folding, and misfolding could theoretically be pro-
vided by the full reconstruction of the conformational transitions
underlying folding pathways. However, experimental approaches
aimed at addressing the dynamics of protein folding are seriously
affected by the trade-off between temporal and spatial resolutions
of available biophysical techniques11. Computer-based technolo-
gies, such as Molecular Dynamics (MD) simulations, could, in
principle, overcome these limitations and help to predict the
evolution in time of protein conformations. In practice, however,
classical MD simulations are not applicable to study many fun-
damental molecular processes, such as the cascade of events
underlying the folding of a typical, biologically relevant poly-
peptide bigger than 80 amino acids and with folding times longer
than a few milliseconds12. More advanced methods, such as
metadynamics or replica exchange, have the advantage that,
under certain conditions, can lead to an exact sampling of the
protein conformations. However, these techniques are too com-
putationally expensive to be applicable to study the folding of
biologically relevant proteins. To solve this issue, we have
developed algorithms that reduce computational costs by
exploiting available experimental information of native struc-
tures13. The reliability of these methods to predict protein folding
mechanisms has been extensively assessed against plain MD
simulations and experiments14. Here, we designed a drug dis-
covery paradigm (named PPI-FIT) based on the rationale of
negatively regulating the level of a given protein by targeting
folding intermediates. The PPI-FIT approach was tested on PrP,
as compelling genetic and experimental evidence indicates that
lowering the expression of this protein could produce therapeutic
benefits in prion diseases without causing major side effects15,16.
Results
Identification of a PrP folding intermediate. The rationale
underlying PPI-FIT is based on designing compounds against the
most kinetically- and thermodynamically relevant folding inter-
mediate of a given protein, in order to stabilize such an inter-
mediate and inhibit its transition to the native form. In a cellular
environment, a stabilized folding intermediate could be recog-
nized by the protein folding quality control machinery as an
improperly folded polypeptide and sent to degradation17.
Therefore, the PPI-FIT approach aims at identifying compounds
capable of post-translationally decreasing the level of a target
protein. We sought to test this drug discovery paradigm on PrP,
based on four aspects: (i) several previous reports indicate that at
least one intermediate is generated along the folding pathway of
PrP18–20; (ii) the genetic suppression of PrP in animal models has
been shown to produce little side effects only later in life21. This
conclusion is also supported by loss-of-function PRNP alleles
observed in healthy human subjects16; (iii) strong experimental
evidence demonstrates that lowering the expression of PrP would
confer therapeutic benefits in prion diseases, and possibly other
neurodegenerative disorders linked to the toxicity-transducing
activity of the protein15,22; (iv) however, multiple previous fail-
ures to target the native conformation of PrP pharmacologically
suggest that this protein could be an undruggable factor23,24. In
light of these considerations, we decided to reconstruct the entire
sequence of events underlying the folding pathway of this protein
at an atomistic level of resolution. The protein consists of a
flexible, N-terminal segment (residues 24–120, human sequence),
and a structured, C-terminal domain (residues 121–231) com-
prising three α-helices and two short β-strands flanking helix-1.
The N-terminal segment is intrinsically disordered, a feature
precluding its use for in silico approaches25. Thus, as a reference
structure, we used the globular domain of human PrP (residues
125–228, PDB 1QLX; Fig. S1). We generated nine unfolded PrP
conformations by thermal unfolding and used rMD to produce 20
folding trajectories for each conformation (making a total of 180
trajectories plotted for their bidimensional probability distribu-
tion in Fig. 1a). A variational approach, called Bias Functional
(BF), was then employed to define the most statistically sig-
nificant folding pathway for each set of trajectories, leading to
nine least biased trajectories (an example is shown in the
Movie S1). Conformations residing within the observed energy
wells in the bidimensional distribution were sampled from each
least biased trajectory (Fig. 1b). The analyses revealed the exis-
tence of an on-pathway PrP-folding intermediate structurally
close to the native state, and explored by all least biased pathways.
Subsequent clustering analysis of the ensemble of conformers
populating the intermediate state enabled the definition of an all-
atom structure for the PrP-folding intermediate (Fig. S2). As
compared with the PrP native conformation, this structure is
characterized by a displaced helix-1 missing its docking contacts
with helix-3, leaving several hydrophobic residues, natively buried
inside the protein core, exposed to the solvent (e.g., Y157, M206,
V209; Fig. 1c).
In silico identification of high-affinity ligands for the
PrP folding intermediate. We employed in silico modeling and
virtual screening techniques to identify small ligands for the
PrP folding intermediate. First, we searched for druggable binding
sites unique in the structure of the latter and not present in the
native PrP conformation. This step was carried out by means of
SiteMap (Schrödinger Release 2017-4) and DoGSiteScorer
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software. The results highlighted the presence of a possible
ligand-binding region, placed between the beginning of helix-1
and the loop that connects the helix-2 with helix-3 (Table S1).
MD simulations refined the structure of a solvent-accessible,
druggable pocket (Table S1) defined by 14 non-continuous
residues (152, 153, 156, 157, 158, 187, 196, 197, 198, 202, 203,
205, 206, 209) (Fig. 1c). This site was the target of a virtual
screening campaign performed by using the BioSolveIT software
and employing the Asinex Gold & Platinum collection of small
molecules (∼3.2 × 105 commercially available compounds). The
obtained poses were filtered according to the predicted estimated
affinity, physicochemical, and ADMET (absorption, distribution,
metabolism, excretion, and toxicity) properties as well as 3D
visualization/assessment of the ligand-binding interactions. In
addition, molecules potentially acting as pan-assay interference
compounds were filtered, and cheminformatics methods for
similarity and clustering analysis were applied to support a
diversity-based selection. Finally, 30 compounds were selected as
promising virtual hits and purchased for biological validation
(Table S2 and Fig. S3).
In vitro validation of in silico hits. PrP biogenesis follows a
trafficking pathway typical of glycosylphosphatidylinositol (GPI)-
anchored polypeptides26. The protein is synthesized directly in
the lumen of the endoplasmic reticulum (ER), where it folds and
receives post-translational processing of the primary structure
(removal of the signal peptide and anchoring of the GPI moiety)
as well as the addition of two N-linked glycans (at Asn-181 and
Asn-197)27. Based on the role of lysosomes in the quality control
of PrP loads, a compound binding to a PrP folding intermediate
may produce a long-living, immature conformer that could be
recognized by the ER quality control machinery, leading to its
degradation by the ER-associated lysosome-dependent autop-
hagy28. Following this principle, the 30 putative ligands were
directly tested in cells for their ability to lower the amount of PrP
at a post-translational level. Each compound was administered for
48 h at different concentrations (1–30 μM) to HEK293 cells stably
expressing mouse PrP. The expression and post-translational
alterations of PrP were detected by western blotting. Compounds
showing an ability to lower the amount or alter the post-
translational processing of PrP (≥30%) at any of the concentra-
tions were tested against a control protein, the Neuronal Growth
Regulator 1 (NEGR-1), a member of the immunoglobulin LON
family. This GPI-anchored molecule follows the same biosynth-
esis pathway as PrP, thus representing an ideal control to evaluate
compound specificity29. We validated four compounds (coded
SM930, SM940, SM950, and SM875), all of them capable of
decreasing the levels of PrP in HEK293 cells without lowering the
control protein NEGR-1 (Fig. 2a–d). Among these, compound
SM875 was selected for further analyses, based on its potency
(docking poses of the compound bound to the PrP folding
intermediate are shown in Fig. 2e).
Synthesis and biological characterization of SM875. In order to
obtain large amounts of the compound for additional assays,
we designed and performed a synthesis scheme for SM875
(Fig. S4). The correct structure of the molecule was verified by
nuclear magnetic resonance (NMR), mass spectrometry (MS),
and infrared (IR) spectroscopy (Fig. S5A–D and Table S3). The
dose-dependent, PrP-lowering activity of the newly synthesized
SM875 molecule was validated using a larger concentration range
(0.01–50 μM) in stably transfected HEK293 cells, allowing the
calculation of the inhibitory concentration at 50% in the low
micromolar range (IC50= 7.87 ± 1.17 μM; Fig. 2a). Next, to rule
out possible artifacts due to the exogenous transfection of PrP, we
tested the effect of SM875 in a human breast cancer cell line (ZR-
75) endogenously expressing human PrP. These cells were iden-
tified among the NCI collection of human tumor cell lines as high
PrP expressors (Fig. S6). Compound SM875 decreased PrP levels
in a dose-dependent fashion also in these cells, in the exact same
concentration range (1–30 μM) observed in transfected HEK293
cells (Fig. 3a). Importantly, SM875 did not alter the level of Thy-
1, another GPI-anchored protein endogenously expressed in ZR-
75 and used as a control (Fig. 3a)30. Consistent with these data,
SM875 reduced the level of PrP in two additional untransfected
cell lines, L929 mouse fibroblasts, and mouse N2a neuroblastoma
cells (Fig. 3b, c). Interestingly, in N2a cells SM875 did not show a
dose–response effect, as PrP decrease was observed only at lower
Fig. 1 All-atom reconstruction of the PrP folding pathway. a Lower-bound approximation of the free energy landscape of the PrP folding obtained from
180 rMD trajectories, plotted as a negative logarithm of the probability distribution expressed as a function of the collective variables Q (fraction of native
contacts) and RMSD. The dashed lines delimit the metastable regions of interest (G≤ 3.7 kBT). b Representative PrP structures of unfolded (U1 and U2),
folding intermediate (I) and native conformations (N). Each conformation represents the cluster center of one of the corresponding populated regions
(structures depicted in transparency are sampled from the same region, showing conformations variability): the first two (corresponding to the unfolded
states U1 and U2) are characterized by RMSD >1.8 nm and a Q < 0.5 (U1), and 1.2 < RMSD < 1.8 nm and a 0.5 <Q < 0.75 (U2); a third one (corresponding
to the intermediate folding state I) with 0.55 < RMSD < 0.90 nm and a 0.65 <Q < 0.85; a fourth one (corresponding to the native state N) with
RMSD < 0.40 nm and Q > 0.80. c Ribbon diagram of the PrP intermediate highlighting the ligand-binding pocket (purple dots) as identified by SiteMap and
DogSiteScorer tools. The purple volume maps the unique druggable pocket identified in the PrP-folding intermediate I. The box shows specific residues
defining the site.
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concentrations (1–10 μM), whereas the protein showed normal
levels at the highest concentration (30 μM). In order to address
this discrepancy, we assessed the levels of PrP mRNA by quan-
titative real-time PCR (RT-PCR). We found that treatment with
SM875 did not decrease PrP mRNA in the different cell lines even
at the highest concentrations, confirming the original rationale
that a compound targeting a folding intermediate of PrP should
lower its expression at a post-translational level (Fig. 3d).
Importantly, only in N2a cells, we observed a robust (>500% at
30 μM), dose-dependent increase of PrP mRNA upon treatment
with SM875, which directly explains the discrepancy observed at
the protein level. This observation also suggests that the com-
pound triggers an over-production of PrP mRNA in these cells,
likely representing a compensatory response aimed at restoring
PrP levels. The compound showed variable intrinsic toxicity in
the different cell lines, with more prominent cytotoxicity in PrP-
transfected HEK293 cells, and progressively lower toxicity in
untransfected HEK293, N2a, ZR-75, and L929 cells, respectively
(Figs. S7, S8). To further corroborate the observed effects of
SM875 on PrP load, we checked whether the compound also
decreases the amount of the protein at the cell surface. HEK293
cells stably transfected with an EGFP-tagged PrP construct were
exposed to SM875, and the localization of PrP was monitored by
detecting the intrinsic green fluorescence of EGFP. In control
conditions, EGFP-PrP localizes almost entirely in the Golgi
apparatus and at the plasma membrane, with the latter giving rise
to a typical “honeycomb-like” staining of the cell surface (Fig. 3e)
31. Compounds altering PrP trafficking, as the phenothiazine
derivative chlorpromazine, have previously been shown to alter
such localization pattern32. Incubation with SM875 for 24 h
induced a drastic reduction of cell surface EGFP-PrP at con-
centrations as low as 1 μM. Collectively, these data confirm that
SM875 selectively reduces the amount of PrP at the post-
translational level and in a cell-independent fashion.
Fig. 2 In vitro validation of selected hits. HEK293 cells expressing mouse PrP or NEGR-1 were exposed to different concentrations of SM875 a, SM930 b,
SM940 c, or SM950 d or vehicle (0.1% DMSO, volume equivalent) for 48 h, lysed in detergent buffer (Tris 10mM, pH 7.4, 0.5% NP-40, 0.5% TX-100, 150
mM NaCl plus EDTA-free Protease Inhibitors), diluted in Laemmli sample buffer and analyzed by western blotting using anti-PrP (D18) or anti-NEGR-1 (R&D,
USA) antibodies. Red arrowheads indicate the expected sizes of mature, fully glycosylated forms of PrP and NEGR-1. The compounds induce a dose-dependent
suppression of PrP (i) but not control protein NEGR-1 (ii). The graphs (iii) show the densitometric quantification of the levels of full-length PrP or NEGR-1 from
different biologically independent replicates. Each signal was normalized on the corresponding total protein lane (detected by UV of stain-free gels) and
expressed as the percentage of the level in vehicle (Vhc)-treated controls (*p < 0.05, **p < 0.01, ***p < 0.005, by one-way ANOVA test). e The picture
illustrates the predicted ligand-binding pose of the R (upper panel) and S (lower panel) SM875 enantiomers into the PrP intermediate druggable pocket.
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SM875 induces the degradation of PrP by the lysosomes. Pro-
teins trafficking through the ER that fail to fold properly are usually
degraded to prevent the accumulation of toxic aggregates. Most
of these aberrantly folded polypeptides undergo retro-translocation
into the cytosol, poly-ubiquitination, and degradation by the
26S proteasome, a process known as ER-associated degradation
(ERAD)33. Although ERAD is the main degradation pathway for
most misfolded ER proteins, GPI-anchored proteins like PrP are
primarily cleared by the so-called ER-to-lysosome-associated
degradation pathway34,35. For example, the expression of disease-
associated, aggregation-prone mutants of PrP in different cells
increases several markers of the autophagy–lysosomal pathway,
such as the autophagosome-specific marker microtubule-associated
protein 1 A/1B-light chain 3-II (LC3-II)28. Here, we sought to test
whether SM875 lowers PrP levels by inducing its lysosomal
degradation. By comparing PrP-transfected and untransfected
HEK293 cells, we observed that SM875 (10–30 μM) increases LC3-
II levels in a PrP-dependent manner (Fig. 4a). Next, we directly
tested the role of lysosomal clearance for the observed PrP-lowering
effect of SM875. As previous data showed that inhibiting degra-
dation pathways in transfected cells could possibly generate over-
transcriptional artifacts of exogenous genes35,36, for these experi-
ments, we relied on ZR-75 cells, expressing PrP endogenously. We
found that autophagy inhibitor Bafilomycin A1 largely rescues
SM875-induced PrP decrease in these cells (Fig. 4b). Of note, the
natural disaccharide trehalose, reported to increase de novo for-
mation of autophagosomes, did not alter the PrP-lowering effects of
SM875 (Fig. S9)37. Collectively, these data indicate that SM875
promotes the degradation of PrP by the autophagy–lysosomal
pathway.
Fig. 3 SM875 lowers the amount of PrP at a post-translational level in different cell lines. Cells were exposed to different concentrations of SM875 or
vehicle (0.1% DMSO) for 48 h, lysed, and analyzed by western blotting. a In ZR-75 cells, SM875 suppresses PrP, but not Thy-1, in a concentration-
dependent fashion. b Similar effects were observed in cultured L929 fibroblasts. c In N2a cells, SM875 shows a dose-dependent lowering effect of PrP at
1–10 μM. However, in contrast to the other cell lines, the compound showed no effect at 30 μM. All signals were detected by using a specific anti-PrP (D18)
or anti-Thy-1 primary antibodies. Red arrowheads indicate the expected sizes of mature, fully glycosylated forms of PrP or Thy-1. Western blotting analysis
(i) and graphs reporting the densitometric quantification of signals (ii) are shown. Each signal was normalized on the corresponding total protein lane
(detected by UV of stain-free gels) and expressed as the percentage of vehicle (Vhc)-treated controls (*p < 0.05, **p < 0.01, ***p < 0.005, by one-way
ANOVA test). d Graphs show the levels of PrP mRNA upon treatment with SM875, as evaluated by RT-PCR. Specific forward and reverse primers were
used to amplify endogenous or exogenous, mouse or human PrP transcripts (see Materials and Methods). Relative quantification was normalized to mouse
or human HPRT (hypoxanthine–guanine phosphoribosyltransferase). Statistical analyses refer to the comparison with vehicle controls (**p < 0.01, ***p <
0.005, by one-way ANOVA test). Dots represent biologically independent replicates. e HEK293 stably expressing a PrP form tagged with a monomerized
EGFP molecule at its N-terminus (EGFP-PrP) were incubated with vehicle (0.1% DMSO) control (i) or SM875 at different concentrations (ii–vi) for 24 h.
Fluorescence of the EGFP protein was then visualized with an Olympus BX51WI microscope equipped with reflected fluorescence. Scale bar 50 μm.
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01585-x ARTICLE
COMMUNICATIONS BIOLOGY |            (2021) 4:62 | https://doi.org/10.1038/s42003-020-01585-x | www.nature.com/commsbio 5
SM875 acts exclusively on nascent PrP. Based on the initial
hypothesis that SM875 acts on an intermediate appearing along
the folding pathway of PrP, we decided to rule out the possibility
that the molecule instead targets native PrP. First, we used
dynamic mass redistribution (DMR), a technique previously
employed to characterize small molecule ligands of PrP. In con-
trast to Fe3+-TMPyP, an iron tetrapyrrole known to interact with
PrP, SM875 (0.1–100 μM) showed no detectable binding to either
human full-length (23–231) or mouse N-terminally truncated
(111–230) recombinant PrP molecules (Fig. 5a). These data
indicate that the compound has no detectable affinity for natively
folded PrP. In order to further validate this conclusion in a cell
system, we turned to previously described RK13 cells expressing
mouse PrP in a doxycycline-inducible fashion (Fig. S10)38. In the
first set of experiments, we turned on the expression of PrP with
doxycycline, in the presence of SM875 (10 μM), brefeldin-1A
(10 μM), an inhibitor of the ER-to-Golgi protein trafficking39, or
vehicle control (0.1% dimethyl sulfoxide (DMSO), volume
equivalent). Cells were then lysed and analyzed by western blot-
ting at different time points (2, 4, 8, or 24 h, Fig. 5b panel i;
Fig. S11A). As expected, in contrast to the typical size of full-
length, diglycosylated PrP (∼35 kDa) obtained in the control
samples, brefeldin-1A induced the accumulation of an immature,
low molecular weight band (∼20 kDa), previously described to
correspond to a N-terminally cleaved PrP molecule formed by a
lysosomal-dependent event40. Interestingly, SM875 induced the
accumulation of a similar PrP band, compatible with its hypo-
thesized activity of targeting a folding intermediate of the protein
(Fig. 5b panel I; and Fig. S11A). Next, we sought to directly test
the effect of the molecule on pre-synthesized, mature PrP. To
pursue this objective, we induced the expression of PrP for 24 h
with doxycycline. We then removed the inducer, waited 4 h,
treated the cells with SM875 or vehicle control, and analyzed PrP
content at different time points (5, 19, and 24 h). In this case, we
found no difference between compound- and control-treated
samples (Fig. 5b, panel ii; and Fig. S11B). The results were further
validated by high-content imaging analysis of immunostained
PrP, which showed that in the same doxycycline-induced RK13
cells, SM875 causes the rapid (as early as 4 h) accumulation of
PrP species in intracellular compartments, preventing their cor-
rect delivery to the cell surface (Fig. 5c). Collectively, these data
show that SM875 acts exclusively on nascent, immature PrP
molecules, whereas the compound exerts no effect on pre-syn-
thesized, mature PrP.
SM875 suppresses prion replication in mouse L929 fibroblasts.
One of the most solid concepts in prion diseases is that sup-
pressing PrP should abrogate prion replication41. The most direct
way to achieve this objective is to silence PrP expression, either
through a selective decrease of its synthesis or increase of its
clearance. Following the observation that SM875 lowers PrP level
by inducing the degradation of a folding intermediate, we tested
the ability of the compound to inhibit the replication of the Rocky
Mountain Laboratories (RML) prion strain in persistently infec-
ted L929 mouse fibroblasts42. We found that SM875 inhibits
prion replication in a dose-dependent fashion, decreasing prion
loads similarly to anti-prion molecule Fe3+-TMPyP, used as a
control (Fig. 6)43.
SM875 induces the aggregation of partially denatured PrP.
Despite the different pieces of evidence collected in silico and in
cell-based assays, the formal demonstration that SM875 directly
targets a folding intermediate of PrP would require a structural
characterization of the complex. Unfortunately, solving the
structure of folding intermediates is limited by the transient
nature of these protein conformers. In an attempt to overcome
this problem, we designed an experimental paradigm aimed at
inducing the appearance of non-native conformers of PrP by
thermally induced partial denaturation (Fig. S12). The underlying
hypothesis is that the PrP folding intermediate predicted by our
in silico analyses could also be reached from the native state by
overcoming an energy barrier so that SM875 could bind and
stabilize it. Here, we explored this possibility by trying to
Fig. 4 SM875 decreases PrP level via the autophagy-mediated lysosomal degradation. a (i) PrP-transfected or untransfected HEK293 cells were treated
with different concentrations of SM875 or vehicle (0.1% DMSO, volume equivalent) and the levels of PrP, LC3-I, and LC3-II were evaluated by western
blotting (indicated by the red arrowheads). As a positive control, cells were treated with 100 μM trehalose (TRE), a disaccharide previously reported to
induce autophagy. (ii) Graphs show the densitometric quantification of LC3-II from independent replicates (n= 8 for PrP-expressing HEK293 cells; n= 5
for untransfected HEK293 cells). Each signal was normalized on the corresponding total protein lane (detected by UV) and expressed as the percentage of
vehicle (Vhc)-treated controls (**p < 0.01, by one-way ANOVA test). b (i) ZR-75 cells were treated with different concentrations of SM875 in the presence
or absence of autophagy–lysosomal inhibitor bafilomycin A1 (BAF, 10 μM) and PrP levels were evaluated by western blotting. (ii) Graphs show the
densitometric quantification of full-length PrP from independent replicates (n= 3). Each signal was normalized on the corresponding total protein lane
(detected by UV) and expressed as the percentage of vehicle (Vhc)-treated controls (**p < 0.01, by one-way ANOVA test).
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Fig. 5 SM875 acts exclusively on non-native, newly synthesized PrP. a DMR was employed to assess whether SM875 has an affinity for the native
conformation of PrP. Different concentrations (0.03–100 μM) of SM875, SM940 or PrP ligand Fe3+-TMPyP (TP), used as a control, were added to label-
free microplate well surfaces on which either (i) full-length, human recombinant PrP (23–230) or (ii) N-terminally deleted mouse recombinant PrP
(111–230) had previously been immobilized. All signals were fitted (continuous lines), when possible, to a sigmoidal function using a 4PL non-linear
regression model. In contrast to SM875 and SM940, TP shows a detectable affinity for both full-length, human, and N-terminally deleted, mouse PrP
molecules (for full-length PrP, Kd = 0.67 ± 0.05, R2 = 0.99). b In order to dissect the effect of SM875 on nascent vs mature, native PrP molecules, we
turned to RK13 cells expressing mouse PrP under control a doxycycline-inducible promoter. (i) PrP expression was induced over 8 h, in the presence of
SM875 (10 μM), brefeldin-1A (BREF, 10 μM), or vehicle (Vhc) control, samples were collected at different time points (indicated) and PrP signals were
visualized by western blotting. Signals were detected by probing membrane blots with anti-PrP antibody (D18). As expected, in control cells, the level of
full-length PrP (red arrowheads) increases in a time-dependent fashion. Conversely, a lower molecular weight band (blue arrowheads) is detected in
brefeldin-treated cells. (ii) Next, we designed an experiment to test the effect of SM875 exclusively on mature, natively folded PrP. PrP expression was
induced for 24 h, in the absence of any additional treatment. Doxycycline was then removed, and after 4 h without inducer, the cells were exposed to
SM875 or Vhc control, and subsequently lysed at different time points (indicated). In this experimental setting, cells are exposed to SM875 only when all
PrP molecules are synthesized and likely in transit to, or already reached the plasma membrane. In these conditions, normal PrP patterns appear in both
compound-treated and Vhc-treated cells. c A high-content approach was employed to the same experimental setting described above by analyzing the
localization of PrP after immunostaining with an anti-PrP antibody (D18) coupled to an Alexa 488 secondary antibody. (i) The expression of PrP was
induced for 2, 4, or 8 h by doxycycline 1× (0.01 mg/mL) or 10× (0.1 mg/mL) and the effect of SM875 (10 μM) incubated with doxycycline 1× was
measured by Harmony software after the image acquisition performed by Operetta Imaging System. Green spots detected in cells were quantified
and plotted against the total green fluorescence relative to each cell. Representative images were acquired at 8 h of incubation, scale bar 50 μm.
(ii) Quantification of the average number of green spots per cell in wells incubated for 2, 4, 8, and 24 h with doxycycline 1× (white bars), doxycycline 10×
(gray bars) and doxycycline 1× + SM875 (red bars). Quantification of at least three independent experiments.
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crystallize the temperature-induced, semi-denatured PrP in
complex with SM875. Recombinant mouse PrP (800 μM) was
heated to 45 °C and slowly cooled to 20 °C using a thermal cycler,
either in the presence or absence of SM875 (2 mM). The high
concentrations of both protein and compounds were compatible
with the crystallization process. Unexpectedly, we observed
massive precipitation (∼40%) of the protein as soon as SM875
was added to the solution, as assayed by UV absorbance. Con-
versely, no appreciable precipitation was detected in vehicle-
treated controls. The remaining soluble PrP molecules gave rise to
“thin needles”-like crystals, appearing after 2–4 days. Importantly,
such crystals were obtained irrespectively of whether the protein
was incubated with SM875 or vehicle. Crystals were weakly and
anisotropically diffracting to 3.7 Å in the best directions, allowing
determination of orthorhombic crystal system and unit cell
dimensions, highly similar to those reported for apo human PrP
in the protein databank (PDB 3HAK) (Table S4). These data
suggest that SM875 targets a thermally induced PrP population,
promoting its precipitation. Conversely, the more native-like PrP
molecules do not bind to SM875 and remain in solution, allowing
crystallization. The observed precipitation of partially denatured
PrP induced by SM875 could reflect an intrinsic propensity of a
PrP folding intermediate to expose hydrophobic residues nor-
mally buried in the native state. In order to better characterize
this effect, we performed a detergent insolubility assay to detect
insoluble aggregates of mouse recombinant PrP (111–230) in the
presence or absence of SM875 upon temperature shift (25, 37, 45,
55 °C; the reported melting temperature for recombinant PrP is
~65 °C)44. Of note, the concentrations of the protein (0.5 μM) and
compound (10 μM) were substantially lower in this assay as
compared to those used for crystallization. We found that, dif-
ferently from vehicle-treated samples, SM875 induced the
aggregation of recombinant PrP in a temperature-dependent
fashion (Fig. 7a). Similar results were obtained with compound
SM940 but not SM935, found positive and negative for PrP
downregulation in cells, respectively (Fig. 3c and Fig. S13).
Interestingly, direct visualization of SM875-induced PrP aggre-
gates by field emission scanning electron microscopy (FESEM)
revealed the presence of amorphous structures appearing as a
multitude of dots showing different sizes and shapes (∼10 nm
diameter) as well as much larger clumps (Fig. S14). Sonication did
not affect the morphology of these aggregates, leading only to the
breakage of the larger structures. Despite being at low resolution,
these results suggest that binding to SM875 induces the formation
of aggregated PrP species that are off-pathway of the folding
process. Importantly, plain MD simulations (21 μs of cumulative
simulation time, Fig. S15) revealed the appearance of a con-
formation highly resembling the folding intermediate occasion-
ally explored by the native PrP state when subjected to a
temperature higher than RT (310 K; Fig. 7b). Collectively, these
data add direct evidence for the interaction of SM875 with a non-
native PrP conformer that could be explored by the natively
folded PrP in a temperature-dependent fashion.
Discussion
We have built on advanced computational techniques to test an
entirely novel method, to the best of our knowledge, for selec-
tively reducing the level of target proteins, which we called PPI-
FIT. This technology is based on the concept of targeting folding
intermediates of proteins rather than native conformations. In the
PPI-FIT method, druggable pockets appearing in specific folding
intermediates observed along the folding pathway of a given
protein are used as targets for virtual screening campaigns aimed
at identifying small ligands for such regions. The underlying
rationale is that stabilizing a folding intermediate of a protein
with small ligands could promote its degradation by the cellular
quality control machinery, which could recognize such artificially
stabilized intermediates as improperly folded species. In this
manuscript, we applied this technology to PrP, identified a spe-
cific intermediate along the folding pathway of the protein, and
then carried out a virtual screening campaign that led to the
discovery of four different chemical scaffolds all capable of
selectively lowering the level of PrP. Extensive characterization of
one of these molecules, called SM875, provided strong experi-
mental support for the notion that targeting folding intermediates
could represent a pharmacological paradigm to modulate protein
loads. From a broader perspective, our data reveal the existence of
a previously unappreciated layer of regulation of protein
expression occurring at the level of folding pathways.
The demonstration that the total level of a protein could be
regulated by targeting a folding intermediate, the concept
underlying the PPI-FIT method, would ultimately require a direct
biophysical characterization of the interaction between the
identified ligands and the predicted folding conformer. Unfor-
tunately, available high-resolution techniques such as X-ray
crystallography or NMR can only be applied to stable molecular
species, while protein folding intermediates are transient and
Fig. 6 SM875 inhibits prion replication in L929 mouse fibroblasts. L929 mouse fibroblasts were infected with the RML prion strain and then propagated
for five sequential passages before exposure to SM875 (indicated concentrations), anti-prion compound Fe3+-TMPyP (TP, 10 μM) or vehicle (0.1%
DMSO) for 48 h. PrPSc loads were then estimated by treating cell lysates with PK and analyzing PrP content by western blotting (i). Signals were detected
by probing membrane blots with anti-PrP antibody (D18). Results show that SM875 inhibits prion replication in a dose-dependent fashion, with the
maximal effect (obtained at 10 μM) comparable to that of TP; (ii) the graph shows the densitometric quantification of all PK-resistant PrP bands from
independent replicates (n≥ 4). Quantification was obtained by densitometric analysis of the western blots, normalizing each signal on the corresponding
PK-untreated lane and expressed as the percentage of vehicle (Vhc)-treated controls (**p < 0.01, *** p < 0.005, by one-way ANOVA test).
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highly dynamic by definition45. Conversely, techniques designed
to study single molecules, like optical tweezers, or to capture very
rapid molecular transitions, such as spectroscopic detection
coupled to stopped-flow methods, are intrinsically low resolution.
In fact, the existence of a folding intermediate of PrP was pre-
viously detected by using similar approaches but never char-
acterized at a structural level18–20. Despite the intrinsic
approximations of all in silico techniques, our computational
platform overcomes the spatiotemporal resolution limits, allow-
ing us to define the atomistic structure of the PrP folding inter-
mediate. Interestingly, the same conformation was occasionally
observed by plain MD simulations of native PrP at 310 K, ruling
out possible biases introduced by the BF method. We used this
information to carry out a virtual screening campaign aimed at
identifying small ligands for such PrP folding conformer. Then, in
light of the aforementioned experimental limits, we designed an
extensive in vitro and cell-based workflow to validate the PPI-FIT
method. First, we identified four compounds, displaying different
chemical scaffolds, all capable of selectively lowering the amount
of PrP. Next, we found that SM875, the most potent among the
positive hits, reduces PrP loads in different cell lines, either
expressing the protein endogenously or exogenously, without
decreasing PrP mRNA levels. Our data also show that SM875
promotes the degradation of nascent PrP molecules by the
autophagy–lysosomal pathway, whereas the molecule neither
binds nor exerts any effect on mature, cell surface PrP. Finally, in
an attempt to co-crystallize the PrP-folding intermediate bound
to SM875, we found that the small molecule induces the pre-
cipitation of PrP species appearing upon mild thermal unfolding.
Collectively, even though we do not formally demonstrate the
interaction of SM875 with the predicted binding pocket, our data
provide strong experimental support for the notion that the
compound acts as by targeting a folding intermediate of PrP
(Fig. 8).
Prion diseases represented a convenient experimental ground
for testing the PPI-FIT approach, as compelling evidence indi-
cates that prion replication and toxicity can be inhibited by tar-
geting a single protein (PrP)15. Theoretical options to achieve this
goal include the ablation of the PrP gene, for example by using
the CRISPR technology46, decreasing its synthesis with specific
antisense oligonucleotides (ASOs)47, or acting directly on cell
surface PrP48, for example, with ligands stabilizing the native fold
and inhibiting its conversion into PrPSc 24,44. Despite encouraging
results obtained with ASOs recently, so far, none of these
approaches has been translated into effective therapies for prion
diseases. Moreover, multiple unsuccessful attempts to identify
small molecules specific for PrP suggest that this protein could be
an undruggable target23,24. Conceptually, a compound like
SM875 capable of selectively promoting the degradation of PrP by
targeting a folding intermediate could be the ideal candidate to
tackle prion diseases pharmacologically, and possibly synergize
with other PrP-silencing strategies. Our data show that SM875
alters the correct maturation of the PrP polypeptide, similarly to
ER-to-Golgi trafficking inhibitor brefeldin 1 A. Moreover, in
prion-infected cells, the PrP-lowering activity of SM875 produces
a strong inhibition of prion replication, comparable to that of the
potent anti-prion compound Fe3+- TMPyP. However, in contrast
to brefeldin 1 A and Fe3+-TMPyP, which are known to be rather
non-specific49, the effect of SM875 is selective for PrP, as
demonstrated by the lack of alterations of other two GPI-
anchored proteins (NEGR-1 and Thy-1). These results indicate
that the further development of PPI-FIT-derived molecules into
compounds administrable in vivo and their subsequent validation
in animal models of prion diseases could represent fundamental
steps to move these classes of anti-prion compounds to the
clinical phase.
A major virtue of the PPI-FIT approach is that it capitalizes on
the cellular quality control machinery to promote the degradation
of the target polypeptide. Such an effect is predicted to be
obtained by targeting the folding process of a protein and it
would not be achieved by putative binding events occurring with
the same intermediate generated by the intrinsic dynamics of the
native form. We envision at least two important limitations for
the applicability of the PPI-FIT method to other proteins. First,
the need for a high-resolution structure of the target, which is
required for the computational reconstruction of the folding
process. Moreover, the method is not applicable to proteins
that fold by a chaperone-assisted mechanism, as this would
Fig. 7 SM875 induces the aggregation of PrP in a temperature-dependent fashion. a Recombinant PrP (111–231) was diluted in a detergent buffer (final
concentration of 0.5 μM), placed at one of the indicated temperatures and incubated for 1 h with either vehicle (Vhc, lanes 1–4) or (lanes 5–8) assay buffer
(blank), SM875, SM940, or SM935 (10 μM). After incubation, samples were subjected to ultracentrifugation, and the resulting detergent-insoluble pellets,
corresponding to the aggregated fraction of PrP, were analyzed by western blotting (i). Signals were detected by probing membrane blots with anti-PrP
antibody (D18). (ii) Graphs show the densitometric quantification of recombinant PrP bands from independent replicates. Each signal was normalized and
expressed as the percentage of the corresponding Vhc-treated sample (*p < 0.05, **p < 0.01, by one-way ANOVA test). b Native PrP (residues 125–228,
PDB 1QLX) was subjected to 21 μs of cumulative (3 × 5 μs+ 2 × 3 μs) MD simulations at 310 K. (i) The RMSD of residues lying within the contact region
between helix-1 and helix-3 (indicated) was computed with respect to the structure of the previously identified PrP-folding intermediate. (i) The graph
shows the probability distribution of the RMSD. The orange arrow indicates the population of PrP conformations resembling the folding intermediate.
(ii) Individual trajectory exploring the PrP-folding intermediate from the native state (highlighted in orange). (iii) Superimposition of the PrP-folding
intermediate identified by the BF method and the conformation reached from the native state, as observed by plain MD.
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undermine the reliability of the folding process prediction as well
as decrease the chance of identifying solvent-exposed pockets.
Even considering these limitations, the PPI-FIT method may be
useful in fields well beyond protein misfolding, as it could theo-
retically be applied to any protein for which the structure has
been solved and not requiring chaperones to fold. Another pos-
sible drawback of PPI-FIT is represented by the location of the
targets, which generally lie within intracellular compartments
such as the ER. Thus, any molecule designed to act by PPI-FIT
should possess the ability to cross lipid bilayers. From this
standpoint, PPI-FIT would be no different than classical phar-
macological approaches directed against intracellular targets or
from other compounds acting as degraders. In fact, a similar
rationale of PPI-FIT is exploited by emerging pharmacological
strategies like the proteolysis targeting chimeras (PROTACs)50.
This approach builds on the principle of designing bi-functional
degraders composed by two covalently linked chemical moieties,
one interacting with the target protein and the second engaging
the E3 ubiquitin ligase, which then targets the polypeptide to
degradation by the proteasome. Notably, two PROTAC com-
pounds against the estrogen receptor and the androgen receptor
have recently reached the clinical phase (trial numbers
NCT03888612 and NCT04072952). However, compounds like
PROTACs target native structures of proteins therefore suffering
from the same limits as classical pharmacological approaches
when applied to undruggable targets like PrP. The PPI-FIT
method theoretically expands the range of druggable conforma-
tions of a polypeptide by targeting alternative structures explored
by the protein along its folding pathway. In fact, the PrP-folding
intermediate provided a solvent-exposed, druggable pocket hid-
den in the native conformation. This feature may result in an
additional advantage: a common problem in pharmacology is
posed by proteins with high structural similarity of their native
conformation, a factor that greatly decreases the chances of
developing selective drugs. However, proteins with highly similar
three-dimensional native folds do not necessarily share folding
pathways, and even proteins with identical folding pathways may
differ for the lifetimes of folding intermediates, which would then
display different affinities for the same compound. Thus, the PPI-
FIT approach could intercept structurally and/or kinetically dif-
ferent folding intermediates and ultimately allow the identifica-
tion of selective ligands even in the case of highly similar proteins.
Finally, it will be interesting to evaluate in the future whether
existing drugs that lower the expression of specific proteins by
unknown mechanisms could be acting in a PPI-FIT-like manner
by targeting folding intermediates.
The observation that the expression of PrP could be modulated
by altering the metabolism of non-native conformers of the
protein appearing along the folding pathway suggests that similar
mechanisms of regulation could be exploited in biology to
Fig. 8 Model for the PPI-FIT-based suppression of PrP. The model schematically illustrates the rationale underlying the PPI-FIT method applied to PrP.
(i and iii) The schematics highlight PrP folding in the presence or absence of a small molecule targeting the PrP intermediate. (ii) PrP follows a typical
expression pathway for GPI-anchored proteins. The polypeptide is directly synthesized into the lumen of the ER, once properly folded and post-
translationally modified it traffics to the Golgi apparatus, where sugar moieties are matured, and then delivered to the cell surface. From the plasma
membrane, PrP molecules could enter into the endosomal recycling pathways, and eventually recycled into the lysosomes. (iv) Aberrantly folded
conformers of PrP, as the case for some previously reported mutant, could be re-routed directly from ER to the lysosomes. In the PPI-FIT method, a small
molecule interferes with PrP expression by binding to a folding intermediate, which gets delivered to the lysosomes, leading to an overall decrease of the
protein at the cell surface.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01585-x
10 COMMUNICATIONS BIOLOGY |            (2021) 4:62 | https://doi.org/10.1038/s42003-020-01585-x | www.nature.com/commsbio
manipulate the levels of several other proteins. Interestingly, such
a mechanism could be directly interconnected with the protein
quality control machinery, potentially conferring an additional
degree of complexity for the spatial and temporal regulation of
proteostasis. Regulating the homeostasis of a folding intermediate
of a protein, rather than just acting on transcription, translation,
or clearance of its mature form, could be energetically favorable
and allow the cell to respond to stimuli more rapidly. Similar
mechanisms may play important roles in several other disease
contexts beyond the one addressed here. For example, altering the
folding pathways of specific homeostatic regulators or immu-
noregulatory factors could be a way for cancer cells to overcome
cellular checkpoints, or for pathogens to evade host defenses. On
an even broader perspective, we believe the existence of functional
folding intermediates of proteins may imply that the evolution of
polypeptide sequences does not act exclusively on native con-
formations, but also on alternative protein conformers transiently
appearing along the folding pathways.
Methods
BF method for folding pathways simulations
General features and software. The BF method is a three-steps procedure that
enables the simulation of protein folding pathways at atomistic level of resolution
and consists of: (i) generation of denatured condition by thermal unfolding,
(ii) productions of folding trajectories starting from the unfolded states and
(iii) scoring of the folding trajectories based on a variational principle. The software
to perform these simulations relies on the MD engine of Gromacs 4.6.5 patched
with the plugin for collective variable analysis Plumed 2.0.2.
Generation of denatured conditions. Unfolded conformations are generated by
thermal unfolding starting from the native structure. This is achieved by per-
forming independent 3 ns trajectories of MD at high temperature (800 K) in the
canonical (NVT) ensemble. For each trajectory, a single denatured conformation is
extracted.
Generation of folding pathways. For each denatured conformation, a set of folding
trajectories are generated by employing the ratchet and pawl molecular dynamics
(rMD) algorithm. In this scheme, the folding progress is described as a function of
a reaction coordinate, defined as z(X):
z Xð Þ 
XN
ijj j<35
Cij Xð Þ  CijðXnativeÞ
h i2
ð1Þ
Where Cij(X) is the contact map of the instantaneous system configuration and
Cij(Xnative) Is the contact map in the reference native state. The reference native
state is obtained by energy minimizing the experimental structure retrieved from
the protein databank. The Cij(X) entries of z(X) interpolate smoothly between 0 and
1 according to the following function:
Cij Xð Þ ¼
1 rij=r0ð Þ6
1 rij=r0ð Þ10 if rij ≤ rc
6=10 if rij ¼ r0





Where rij is the Euclidean distance between the ith and the jth atom, r0 is a typical
distance defying residue contacts (set to 7.5 Å) and rc is a cutoff distance (set to
12.3 Å) beyond which the contact is set to 0. In rMD, the protein evolves according
to plain MD as long as the reaction spontaneously proceeds towards the native
state (i.e., lowering the value of the z(x) coordinate). On the other hand, when the
chain tries to backtrack along z(X), an external biasing force is introduced that
redirects the dynamics towards the native state. The biasing force acting on a given
atom, FirMD, is defined as:
FrMDi ¼
kr∇izðXÞ  zðXÞ  zmðtÞ½  if zðXÞ> zmðtÞ
0 if zðXÞ≤ zmðtÞ

ð3Þ
Where zm(t) indicates the smallest value of the reaction coordinate z(X) up to time t
and kr is a coupling constant.
Selection of least biased trajectory. For each set of trajectories starting from the same
initial condition, the folding pathway with the highest probability to realize in the
absence of external biasing force is selected. This scheme is applied by first defining
a folding threshold: a trajectory is considered to have reached the folded state if its
root mean squared deviation of atomic positions (RMSD) compared with the
native target structure is ≤4 Å. Then, the trajectories successfully reaching the








dτ FrMDi ðX; τÞ
 2 ð4Þ
Where t is the trajectory folding time, mi and γi are the mass and the friction
coefficient of the ith atom and FirMD is the force acting on it. The folding trajectory
minimizing the BF for each set is referred to as Least Biased (LB) trajectory.
Computational analysis of the cellular PrP
Structure and topology of the C-terminal domain of the cellular PrP. The native
structure of the C-terminal domain of human PrP was retrieved from PDB 1QLX,
the structure spans from residue 125 to 228 and contain the structured globular
domain of PrP. Protein topology for folding simulations was generated in Gromacs
4.6.5 using Amber99SB-ILDN force field in TIP3P water. Protein topology for plain
MD simulations was generated in Gromacs 2018 using Charmm36m force field in
TIP3P water.
Folding simulations of PrP. The native structure of the C-terminal domain of
human PrP (PDB 1QLX) was positioned in a dodecahedral box with 40 Å mini-
mum distance from the walls. The box was filled with TIP3P water molecules and
neutralized with three Na+ ions. The system was energy minimized using the
steepest descent algorithm. NVT equilibration was then performed for 500 ps at
800 K using the V-rescale thermostat with positional restraints on heavy atoms.
Restraints were then removed and nine independent 3 ns of plain MD were per-
formed in the NVT ensemble at 800 K, yielding nine denatured conformation. Each
initial condition was repositioned in a dodecahedral box with 15 Å minimum
distance from the walls, energy minimized using the steepest descent algorithm and
then equilibrated first in the NVT ensemble (using the Nosé-Hoover thermostat at
350 K, τT= 1 ps) and then in the NPT ensemble (using the Nosé-Hoover ther-
mostat at 350 K, τT= 1 ps, and the Parrinello–Rahman barostat at 1 bar, τP= 2
ps). For each initial condition, 20 trajectories were generated by employing the
rMD algorithm in the NPT ensemble (350 K, 1 bar). Each trajectory consists in
1.5 × 106 rMD steps generated with a leap-frog integrator with time-step of 2 fs.
Frames were saved every 5 × 102 steps. The ratchet constant kr was set to 5 × 10−4
kJ/mol. Non-bonded interactions were treated as follow: Van-der-Waals and
Coulomb cutoff was set to 16 Å, whereas Particle Mesh Ewald was employed for
long-range electrostatics. For each set of trajectories, the BF scheme was applied
with additional filtering on the secondary structure content for folding definition.
In particular, trajectories reaching a final conformation with <85% of average
secondary structure content compared to the NMR structure were not considered
in the ranking.
Analysis of the folding trajectories. RMSD was computed using Gromacs while the
fraction of native contacts (Q) was computed using VMD 1.9.2. A lower-bound
approximation of the energy landscape G(Q, RMSD) was generated by plotting the
negative logarithm of the 2D probability distribution of the collective variables Q
and RMSD, obtained from the 180 rMD trajectories (115 × 115 bins). Protein
conformations belonging to the LB trajectories and spanning over the energetic
wells of interest (G ≤ 3.7 kBT) were sampled. Conformations belonging to the
intermediate state were clustered by using the k-mean approach in R-Studio51
employing the following metrics for defining a distance between two structures:




Cij XAð Þ  CijðXBÞ
h i2
vuut ð5Þ
Where D(XA, XB) is the distance metrics between two protein conformations,
Cij(XA) and Cij(XB) are the contact map entries of the conformations A and B
respectively (defined in Eq. 2). The appropriate number of cluster (k= 3) was
selected using the elbow method. The representative configuration of each cluster
was selected by calculating the average contact map of the cluster conformations
and then extracting the structure minimizing the distance D(XA, XB) between itself
and the average contact map. Data were represented using the Matplotlib library in
python, the 2D [Q, RMSD] energy plot was smoothed with a Gaussian kernel.
Images of the protein conformations were produced using UCSF Chimera.
Plain MD simulations of native PrP. The native structure of the C-terminal domain
of human PrP (PDB 1QLX) was positioned in a dodecahedral box with 11 Å
minimum distance from the walls. The box was filled with TIP3P water molecules,
neutralized with counterions and brought to a final 150 mM NaCl concentration.
The system was energy minimized using the steepest descent algorithm. NVT
equilibration was then performed for 1 ns at 310 K using the V-rescale thermostat
followed by 1 ns of NPT equilibration with the V-rescale thermostat and the
Parrinello–Rahman Barostat at 310 K and 1 Bar (NVT and NPT equilibrations
were carried out with positional restraints on heavy atoms). The equilibrations
were repeated 5 times (each one starting from the energy minimized structure)
giving rise to five initial conditions. For each initial condition, a single MD tra-
jectory was launched (NPT, 310 K, 1 Bar), yielding a total of three trajectories (5 μs
each) and two trajectories (3 μs each). The leap-frog algorithm (dt= 2 fs) was
employed to perform these simulations. Non-bonded interactions were treated as
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follow: Van-der-Waals and Coulomb cutoff was set to 12 Å, whereas Particle Mesh
Ewald was employed for long-range electrostatics. A force-switch Van-der-Waals
modifier with switch radius of 10 Å was used.
Analysis of plain MD trajectories. The Cα RMSD of residues residing in the contact
region between helix-1 and helix-3 (144–156 and 201–208) was computed with
respect to the structure of the PrP folding intermediate previously identified using
the BF method. The RMSD computed for each nanosecond of trajectory was then
used to generate a probability distribution of this quantity.
Computer-aided drug discovery analyses
Consensus approach for druggable ligand-binding site identification. A consensus
approach relying on SiteMap (Schrödinger Release 2017-4: SiteMap, Schrödinger)52
and DoGSiteScorer53 analysis has been applied to find and evaluate druggable
binding pocket. Default parameters were used for both tools. Specific structural
properties, namely volume, depth, enclosure/exposure and balance and different
druggability scores were computed for each identified site. In particular, the
exposure, enclosure and depth properties provide a different measure of how the site
is prone to be a deep pocket. For the exposure property, the lower the score, the
better the site, with the average value for tight-binding sites found to be 0.49.
Conversely, higher scores are preferred for the enclosure descriptor, with the
average enclosure score for a tight-binding site being 0.78. On the other hand, the
balance property of SiteMap expresses the ratio between the relative hydrophobic
and hydrophilic character of a pocket. This fraction has proven to be a highly
discriminating property in distinguishing between druggable and undruggable
pockets, with a mean value for tight-binding site equal to 1.6. Besides the global
pocket descriptors, the applied tools provide automated methods for a quantitative
estimation of druggability. SiteMap predicts a site score (SiteScore) and druggabilty
score (DScore) through a linear combination of only three single descriptors: the
size of the binding pocket, its enclosure, and a penalty for its hydrophilicity. The two
scores differ in the coefficients, which are based on different training sets and
strategies. A score value of ≥ 0.8 and ≥ 0.98 for SiteScore and DScore, respectively,
has been reported to accurately distinguish between drug-binding and non-drug-
binding sites. DoGSiteScorer also generates two scores, i.e., SimpleScore and a
druggability score (DrugScore), which range from zero to one. The druggability
cutoff for both scores is set to 0.5, indicating that targets with score above
this value are considered as being druggable. Against this backdrop and
considering the innovative character of the target herein reported (i.e., a folding
intermediate structure), less stringent thresholds were thus selected in the search
of druggable pockets to be explored in virtual screening: volume ≥ 300 Å3; depth
≥ 10 Å; balance ≥ 1.0; exposure ≤ 0.5; enclosure ≥ 0.70; SiteScore ≥ 0.8; DScore
≥ 0.90; DrugScore ≥ 0.5; SimpleScore ≥ 0.5 (Table S1).
Identification of a druggable pocket in the PrP folding intermediate. The previously
described consensus approach allowed the identification of a possible ligand-
binding region in the PrP folding intermediate, placed between the beginning of
helix-1 and the loop that connects the helix-2 and helix-3 (Table S1). MD simu-
lation were carried out to extract the most druggable conformation of this region,
suitable for our virtual screening purpose. The folding intermediate was prepared
with the Schrödinger’s Protein Preparation Wizard. During the preparation, the
hydrogen bonding networks were optimized through an exhaustive sampling of
hydroxyl and thiol groups. The N- and C- terminal residues were capped with ACE
and NMA groups, respectively. Then, hydrogen atoms and protein side chains were
energy minimized using the OPLS3 force field. The obtained structure was (i)
solvated by TIP3P water molecules in a cubic simulation box of 12.5 Å distant from
the protein in every direction, (ii) neutralized by addition of three Na+ ions, and
(iii) equilibrated for 100 ps of MD simulation (NPT ensemble) at 300 K using the
Langevin thermostat. In such a simulation, the relative positions of the Cα atoms
were kept fixed (force constant 1 kcal/mol), in order to exclusively sample the
arrangement of the side chains. Short-range electrostatic interactions were cutoff at
9 Å, a RESPA integrator was used with a time-step of 2 fs, and long-range elec-
trostatics were computed every 6 fs. MD simulations were performed using the
OPLS3 force field in Desmond 5.0 software (Schrödinger Release 2017-4: Desmond
Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2017) and run
for 50 ns. Recording interval was set to 50 ps, allowing the collection of 1001
frames. The trajectory was clustered using the “Desmond trajectory clustering” tool
in Maestro (Maestro-Desmond Interoperability Tools, Schrödinger) based on the
RMSD of residues 152, 153, 156, 157, 158, 187, 196, 197, 198, 202, 203, 205, 206,
and 209 (i.e., the residues composing the interested site). A hierarchical clustering
was performed to obtain 10 clusters of the explored site. The centroid of each
cluster was then selected as representative structure and subjected to in silico
ligand-binding site prediction and druggability assessment by using the above-
mentioned consensus methods involving DogSiteScorer and SiteMap analysis
(Table S1).
Virtual chemical library preparation. The Asinex Gold & Platinum Library was
downloaded from the Asinex webpage (∼3.2 × 105 commercially available com-
pounds, www.asinex.com). A first round of ligand preparation was performed in
LigPrep (Schrödinger Release 2017-4: LigPrep, Schrödinger). In this step, the dif-
ferent tautomeric forms for undefined chiral centers were created. By contrast, for
specified chirality, only the specified enantiomer was retained. Subsequently, the
compounds were imported within SeeSAR (SeeSAR version 5.6, BioSolveIT
GmbH), that assigned the proper geometry, the protonation state and the tauto-
meric form of the compounds using the ProToss method. A final library of ∼4.3 ×
105 docking clients was thus obtained.
Identification of in silico hits through virtual screening. The virtual screening
workflow was developed by using the KNIME analytic platform and the BioSolveIT
KNIME nodes. Specifically, the workflow was organized as follows: (i) the “Prepare
Receptor with LeadIT” node was used for protein preparation and docking para-
meters definition in LeadIT (LeadIT version 2.2.0; BioSolveIT GmbH,
www.biosolveit.de/LeadIT). The binding site was defined on the basis of the resi-
dues composing the identified druggable pocket (Fig. S2C). The residue protona-
tion states, as well as the tautomeric forms, were automatically assessed in LeadIT
using the ProToss method, that generates the most probable hydrogen positions on
the basis of an optimal hydrogen bonding network using an empirical scoring
function; (ii) the “Compute LeadIT Docking” node was selected to perform the
docking simulations of the ∼4.3 × 105 docking clients by using the FlexX algo-
rithm54. Ten poses for each ligand were produced; (iii) the “Assess Affinity with
HYDE in SeeSAR” node generated refined binding free energy (i.e., ΔG) and
estimated HYDE affinity (KiHYDE) for each ligand pose using the HYDE rescoring
function;55 (iv) for each ligand, the pose with the lowest KiHYDE was extracted. Only
compounds with a predicted KiHYDE range below 5 μM were retained for the fol-
lowing steps; (v) the rescored poses were filtered based on physicochemical and
ADME filters using the Optibrium models integrated in SeeSAR (Optibrium 2018).
In particular the following filters were used: 2 ≤ LogP ≤ 5, where LogP is the cal-
culated octanol/water partition coefficient; 1.7 ≤ LogD ≤ 5, where logD is the
calculated octanol/water distribution coefficient; TPSA ≤ 90; where TPSA is the
topological polar surface area; LogS ≥ 1, where a LogS corresponds to intrinsic
aqueous solubility greater than 10 μM; LogS7.4 ≥ 1, where LogS7.4 is the intrinsic
aqueous solubility at pH of 7.4; HIA=+ , where HIA is the classification for
human intestinal absorption (predicts a classification of “+” for compounds which
are ≥ 30% absorbed and “−” for compounds which are < 30% absorbed); 300 ≤
MW ≤ 500, where MW is molecular weight; number of rotable bonds ≤ 3; PgP
category=−, where PgP category is the classification of P-glycoprotein transport
(the compound must belong to the “−” category to avoid the active efflux); number
of hydrogen bond donors ≤ 3; number of stereocenters ≤ 1. In addition, molecules
potentially acting as pan-assay interference compounds were discharged. This
approach produced a list of 275 virtual hits, which were first submitted to a
diversity-based selection. For each compound, a binary fingerprint was derived by
means of the canvasFPgen utility provided by Schrödinger (Fingerprint type:
MolPrint2D; precision:XP) (Schrödinger Release 2017-4: Canvas, Schrödinger).
Using the created fingerprint, the 10 most different compounds (i.e., ASN
03578729, ASN 15755504, ASN 16356773, ASN 17325626, ASN 19380113, BAS
00312802, BAS 00340795, BAS 00382671, BAS 01058340, BAS 01849776) were
extrapolated by applying the canvasLibOpt Schrodinger utility (Schrödinger
Release 2017-4: Canvas, Schrödinger). In addition, visual inspection guided the
selection of promising ligands based on the predicted binding mode and the
interactions established with the identified binding pocket. In total, 30 molecules
were selected, 8 from the diverse selection and 22 after visual inspection (Fig. S3
and Table S2). Indeed, even though 10 diverse compounds were originally chosen,
BAS 00340795 was not in stock and ASN 03578729 was later replaced by its close
analog ASN 05397475, selected by 3D visualization and endowed with a better
predicted affinity.
Chemical synthesis of SM875
Reagents and instrumentation. The reagents (Sigma Aldrich) and solvents (Merck)
were used without purification. The reaction yields were not optimized and cal-
culated after chromatographic purification. Thin layer chromatography (TLC) was
carried out on Merck Kieselgel 60 PF254 with visualization by UV light.
Microwave-assisted reactions were carried out using a mono-mode CEM Discover
reactor in a sealed vessel. Preparative thin layer chromatography (PLC) on 20 × 20
cm Merck Kieselgel 60 F254 0.5 mm plates. High-performance liquid chromato-
graphy (HPLC) purification was performed by a Merck Hitachi L-6200 apparatus,
equipped with a diode array detector Jasco UVIDEC 100 V and a LiChrospher
reversed phase RP18 column, in isocratic conditions with eluent acetonitrile/water
1:1, flow 5mLmin−1, detection at 254 nm. IR spectrum of the final product was
recorded by using a FT-IR Tensor 27 Bruker spectrometer equipped with atte-
nuated transmitter reflection device at 1 cm−1 resolution in the region Δν 400 ÷
1000 cm−1. A thin solid layer was obtained by the evaporation of the chloroform
solution in the sample. The instrument was purged with a constant dry nitrogen
flow. Spectra processing was made using Opus software packaging. NMR spectra
were recorded on a Bruker-Avance 400 spectrometer by using a 5 mm BBI probe
1H at 400MHz and 13C at 100MHz in CDCl3 relative to the solvent residual
signals δH 7.25 and δC 77.00 ppm, J values in Hz. Structural assignments are
confirmed by heteronuclear multiple bond correlation experiments. ESI-MS spectra
were taken with a Bruker Esquire-LC mass spectrometer equipped with an elec-
trospray ion source, by injecting the samples into the source from a methanol
solution MS conditions: source temperature 300 °C, nebulizing gas N2, 4 L min−1,
cone voltage 32 V, scan range m/z 100–900. LC-ESI-MS spectrum was acquired
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using a C-18 Kinetex 5 μm column, eluting with acetonitrile/water 70:30, flow
1mLmin−1 using ESI source as detector in positive ion mode. High-resolution
ESI-MS measurement for the final product, including tandem MS2 fragmentation
experiments, were obtained by direct infusion using an Orbitrap Fusion Tribrid
mass spectrometer.
Synthesis of SM875. The target product SM875 was obtained according the syn-
thetic strategy reported in Fig. S4. The sequence involves the preparation of the
precursor 1-(4-bromophenyl)-1H-pyrazol-5-amine, which was used in a fol-
lowing three-component reaction with 4-hydroxy-3-methoxybenzaldehyde and
Meldrum acid (2,2-dimethyl-1,3-dioxane-4,6-dione) according to a modified
method56. The 1-(4-bromophenyl)-1H-pyrazol-5-amine was synthesized starting
from 4-(bromophenyl) hydrazine that was obtained from the commercial
hydrochloride by treatment with a saturated NaHCO3 aqueous solution (50 mL),
followed by dichloromethane extraction (50 mL ×3), treatment with anhydrous
Na2SO4 and evaporation. To a magnetically stirred solution of 4-(bromophenyl)-
hydrazine (100 mg, 0.53 mM, in 5 mL ethanol 5), ethyl-2-cyano-3-ethoxyacrylate
(89.6 mg, 0.53 mM) was added and refluxed for 2 h. The reaction mixture was
concentrated in vacuo, the residue was suspended in 1:1 methanol/2 M NaOH
aqueous solution (5 mL) and refluxed for 1 h. After cooling, the mixture was
neutralized with 1 M HCl aq. solution (5 mL) and concentrated in vacuo using a
water bath at 40 °C. The residue was heated at 180 °C for 10 min, suspended in
ethanol after cooling and stored overnight at 4 °C. The supernatant was recov-
ered and concentrated to give a residue which was stirred in the presence of a
NaHCO3 solution (10 mL). Extraction with ethyl acetate (10 mL ×3), followed by
the treatment with anhydrous Na2SO4 of the combined organic phases and
concentration in vacuo gave the product (79 mg, 61%), which was used in the
following three-component reaction. The successful synthesis of 1-(4-bromo-
phenyl)-1H-pyrazol-5-amine was verified by 1H-NMR [δH 7.58 (d, J 8.7 Hz,
H-3’and H-5’), 7.47 (d, J 8.7 Hz, H-2’and H-6’), 7.41 (s, H-3), 5.62 (s, H-4)] and
ESI-MS (m/z 239.8 [M+H]+). In the last reaction step, 1-(4-bromo-phenyl)-
1H-pyrazol-5-amine (79 mg, 0.33 mM), 4-hydroxy-3-methoxybenzaldehyde (41
mg, 0.27 mM) and 2,2-dimethyl-1,3-dioxane-4,6-dione (46 mg, 0.32 mM) in
ethanol (5 mL) were refluxed under stirring for 2.5 h, or alternatively by replacing
the conventional heating with microwave irradiation at 110 °C for 1 h. The
reaction mixture was then cooled to room temperature (RT) and dried in vacuo.
The raw product was purified by silica preparative thin layer chromatography
(PLC) eluting with n-hexane/ethyl acetate (1:1). The band collected at retention
factor 0.4 was first used for structural characterization and then injected into
preparative HPLC (RP18 column, acetonitrile/water 1:1, UV detection at 254 nm,
flow 5 mL min−1, retention time 4.5 min) to give the target product (for use on
cell cultures) as a white powder after evaporation of the eluent: 34 mg, 25% with
reflux in ethanol; a yield of ∼25% is also obtained with microwave irradiation.
Structural characterization of SM875. NMR, HRESI-MS spectra together with LC-
MS (UV, EIC, and MS) are reported in Fig. S5 and Table S3. Figure S5B, relative to
HRESI-MS, reports the results of single measurements, whereas the average of 80
measures in positive ion mode is reported here: HRESI(+)MS: m/z 414.0443 ±
0.0013, [M+H]+ (calculated for C19H1779BrN3O3= 414.0448); HRESI(+)MS/MS
on the fragment ions of 414.0443: m/z 399.0205 ± 0.0019, [M+H-CH3]+
(calculated for C18H1479BrN3O3= 399.0213); m/z 372.0335 ± 0.0019, [M+H-
C2H2O]+ (calculated for C17H1579BrN3O2 = 372.0342); m/z 289.9918 ± 0.0017,
[M+H-C7H8O2]+ (calculated for C12H979BrN3O= 289.9929).
Cell-based and biochemical assays
Cell cultures and treatments. Cell lines used in this paper have been cultured in
Dulbecco’s Minimal Essential Medium (Gibco, #11960-044), 10% heat-inactivated
fetal bovine serum (Δ56-FBS), 50 U/mL penicillin, and 50 μg/mL streptomycin
(Pen/Strep, Corning #20-002-Cl), non-essential amino acids (Gibco, #11140-035)
and L-Glutamine (Gibco, #25030-024), unless specified differently. HEK293 and
N2a cells were obtained from ATCC (ATCC CRL-1573 and CCL-131, respec-
tively). We used a subclone (A23) of HEK293 stably expressing a mouse wild-type
PrP or an EGFP-PrP construct, both already described and characterized pre-
viously32. L929 mouse fibroblasts and inducible RK13 cells were kindly provided by
Ina Vorberg (DZNE, Bonn, Germany)42 and Didier Villette (INRA, Toulouse,
France)38, respectively. Human cancer cell lines (H358, ZR-75, A549, H460, MCF7,
H1299, SKBR3, and T47D), all belonging to the NCI collection of human cancer
cell lines, were kindly provided by Valentina Bonetto (Mario Negri Institute, Milan,
Italy). All the cell lines were originally authenticated by the provider (ATCC or
NCI) and tested for possible mycoplasma contamination every two months. Cells
were passaged in T25 flasks or 100 mm Petri dishes in media containing 200 μg/mL
of Hygromycin or 500 μg/mL of G418 and split every 3–4 days. Every cell line
employed in this study has not been passaged more than 20 times from the original
stock. Compounds used in the experiments were resuspended at 30 or 50 mM in
DMSO, and diluted to make a 1000× stock solution, which was then used for serial
dilutions. A 1 μL aliquot of each compound dilution point was then added to cells
plated in 1 mL of media with no selection antibiotics. For pulse experiments,
inducible RK13 cells were seeded on 24-well plates at a confluence of 50%. After
24 h cells were treated with doxyciclin (0.01 mg/mL) or vehicle (0.1% DMSO), in
the presence or absence of brefeldin 1 A (BREF 10 μM) or SM875 (10 μM). At the
end of each time-point (2, 4, 8 and 24 h) cells were washed with PBS and then lysed
in lysis buffer. For chase experiments, RK13 cells were seeded on 24-well plates at a
confluence of 30%. After 24 h cells were treated with doxyciclin (0.01 mg/mL) for
24 h. The medium containing doxycycline was then removed and cells kept in fresh
medium for 4 h before adding SM875 (10 μM). After 5, 19, and 24 h of incubation
cells wells were washed with PBS and lysed.
Plasmids. The EGFP-PrP construct contains a monomerized version of EGFP
inserted after codon 34 of mouse PrP57. The identity of all constructs was con-
firmed by sequencing the entire coding region. All constructs were cloned into the
pcDNA3.1(+)/hygro expression plasmid (Invitrogen). The Strep-FLAG pcDNA3.1
(+)/G418 NEGR-1 and the anti-NEGR-1 primary antibody were kindly provided
by Giovanni Piccoli (University of Trento, Italy)58. All plasmids were transfected
using Lipofectamine 2000 (Life Technologies), following manufacturer’s
instructions.
Western blotting and antibodies. Samples were lysed in lysis buffer (Tris 10 mM,
pH 7.4, 0.5% NP-40, 0.5% TX-100, 150 mM NaCl plus complete ethylenediami-
netetraacetic acid-free Protease Inhibitor Cocktail Tablets, Roche, #11697498001),
diluted 2:1 in 4× Laemmli sample buffer (Bio-Rad) containing 100 mM Dithio-
threitol (CAS No. 3483-12-3, Sigma Aldrich), boiled 8 min at 95 °C and loaded on
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), using 12%
acrylamide pre-cast gels (Bio- Rad) and then transferred to polyvinylidene fluoride
(PVDF) membranes (Thermo Fisher Scientific). Membranes were blocked for 20
min in 5% (w/v) non-fat dry milk in Tris-buffered saline containing 0.01% Tween-
20 (TBS-T). Blots were probed with anti-PrP antibodies D18 (kindly provided by
D. Burton, The Scripps Research Institute, La Jolla, CA) or 6D11 (1:5000) in BSA
3% in TBS-T overnight at 4 °C, anti-NEGR-1 antibody (1:5000, kindly provided by
Giovanni Piccoli, University of Trento, Italy), anti-Thy-1 (1:5000, OX7, Abcam) or
anti-LC3 (1:2000, ab51520, Abcam), all in 5% (w/v) non-fat dry milk. After
incubation with primary antibodies, membranes were washed three times with
TBS-T (10 min each), then probed with a 1:8000 dilution of horseradish conjugated
goat anti-human (Jackson Immunoresearch) or anti-mouse (Santa Cruz) IgG for 1
h at RT. After two washes with TBS-T and one with Milli-Q water, signals were
revealed using the ECL Prime western blotting Detection Kit (GE Healthcare), and
visualized with a ChemiDoc XRS Touch Imaging System (Bio-Rad). In all the
experiments, with the exception of PK-treated samples, the final quantification of
proteins detected by primary antibodies were obtained by densitometric analysis of
the western blots, normalizing each signal on the corresponding total protein lane
(obtained by the enhanced tryptophan fluorescence technology of stain-free gels,
BioRad).
Dot blotting. Samples were spotted on PVDF membrane in a 96-well dot blot
system. A 96-well dot blot apparatus (Schleicher & Schuell) was set up with a 0.45-
μm-pore-size PVDF membrane (Immobilon-P; Millipore), and each dot was rinsed
with 500 μL of TBS. Under vacuum, cell lysates diluted 1:10 in TBS were added to
the apparatus and rinsed with 500 μL of TBS. The membrane was then blocked
with 5% milk-0.05% Tween-20 (Sigma) in TBS (TBS T-milk) for 30 min and
probed with the anti-PrP antibody 6D11 (1:4000) followed by goat anti-mouse IgG
(Pierce). Signals were revealed using enhanced chemiluminescence (Luminata, Bio-
Rad) and visualized by a ChemiDoc XRS Touch Imaging System (Bio-Rad).
Quantitative real-time PCR. Following treatments, cells were harvested from 24-
well plates and RNA was extracted using TRIzol (Invitrogen) or RNeasy Plus mini
kit (Quiagen). An 800-ng aliquot per each sample was reverse transcribed using
High Capacity cDNA Reverse Transcription kit (Applied Biosystems) according to
the manufacturer’s instructions. Quantitative RT-PCR was performed in a CFX96
Touch thermocycler (Bio-Rad) using PowerUp SYBR Green Master mix (Invi-
trogen) for 40 cycles amplification. Mouse PrP set 1 and set 2 were used to amplify
endogenous and transgenic PrP, respectively (Table 1). Relative quantification was
normalized to mouse or human HPRT (hypoxanthine–guanine phosphoribosyl-
transferase) as a housekeeping control.
Immunofluorescence and high-content imaging. Immunocytochemistry was per-
formed on inducible RK13 cells treated for 2, 4, 8, or 24 h with doxycycline 0.01
(1×) or 0.1 (10×) mg/mL, in the presence or absence of SM875 (10 μM). Cells were
seeded on CellCarrier-384 Ultra microplates (Perkin Elmer) at a concentration of
6000 cells/well, grown for ~24 h, to obtain a semi-confluent layer (60%) and then
treated with the compound. Cells were fixed for 12 min at RT by adding methanol-
free paraformaldehyde (Thermo Fisher Scientific) to a final concentration of 4%.
Wells were then washed three times with PBS, and permeabilized for 1 min with
PBS containing a final concentration of 0.1% Triton X-100. Wells were washed
three times with PBS and cells were incubated with blocking solution (FBS 2% in
PBS) for 1 h at RT. The anti-PrP primary antibody (D18) was diluted in the
blocking solution and added to the wells to a final concentration of 1:400. After
three washes with PBS, the secondary antibody (Alexa 488-conjugated goat anti-
human IgG diluted 1:500 in blocking solution) was incubated for 1 h at RT.
Hoechst 33342 (Thermo Fisher Scientific) diluted in 0.5 mM PBS was then added
after two additional washes. In another set of experiments, cells expressing EGFP-
PrP were plated on CellCarrier-384 Ultra microplates (Perkin Elmer) at a
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concentration of 12.000 cells/well and grown for ~24 h, to obtain a semi-confluent
layer (60%). SM875 was administered at a final concentration of 0.1, 0.3, 1, 3, or
10 μM, in two replicate wells. Vehicle (0.1% DMSO, volume equivalent) was used
as a negative control. Cells were treated for 24 h and then fixed for 12 min at RT by
adding methanol-free paraformaldehyde (Thermo Fisher Scientific) to a final
concentration of 4%. Plates were then washed twice with PBS and counterstained
with Hoechst 33342. The cell localization of EGFP-PrP and inducible PrP was
monitored using an Operetta High-Content Imaging System (Perkin Elmer).
Imaging was performed in a widefield mode using a ×20 High NA objective (0.75).
Five fields were acquired in each well over two channels (380–445 Excitation-
Emission for Hoechst and 475–525 for EGFP and Alexa 488). Image analysis was
performed using the Harmony software version 4.1 (Perkin Elmer).
Cell viability. Cells were seeded on 24-well plates at ∼60% confluence. Compounds
at different concentrations or vehicle control (0.1% DMSO, volume equivalent)
were added after 48 h, medium was replaced the second day, and then removed
after a total of 48 h of treatment. Cells were incubated with 5 mg/mL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Aldrich) in
PBS for 15 min at 37 °C. After carefully removing MTT, cells were resuspended in
500 μL DMSO, and cell viability values obtained by a plate spectrophotometer
(BioTek Instruments, VT, USA), measuring absorbance at 570 nm.
Production of recombinant PrP. RecHuPrP23-231 was expressed by competent
Escherichia coli Rosetta (DE3) bacteria harboring pOPIN E expression vector59.
Bacteria from a glycerolate maintained at −80 °C were grown in a 250 mL
Erlenmeyer flask containing 50 mL of LB broth overnight. The culture was then
transferred to two 2 L Erlenmeyer flasks containing each 500 mL of minimal
medium supplemented with 3 g/L glucose, 1 g/L NH4Cl, 1 M MgSO4, 0.1 M CaCl2,
10 mg/mL thiamine, and 10 mg/mL biotin. When the culture reached an OD600 of
∼0.9–1.2 AU, Isopropyl β-D-1-thiogalactopyranoside was added to induce
expression of PrP overnight under the same temperature and agitation conditions.
Bacteria were then pelleted, lysed, inclusion bodies collected by centrifugation, and
solubilized in 20 mM Tris-HCl, 0.5 M NaCl, 6 M Gnd/HCl, pH= 8. Although the
protein does not contain a His-tag, purification of the protein was performed with
a histidine affinity column (HisTrap FF crude 5 mL, GE Healthcare Amersham)
taking advantage of the natural His present in the octapeptide repeat region of PrP.
After elution with buffer containing 20 mM Tris-HCl, 0.5 M NaCl, 500 mM imi-
dazole and 2M guanidine-HCl, pH= 8, the quality and purity of protein batches
was assessed by BlueSafe (NZYTech, Lisbon) staining after electrophoresis in SDS-
PAGE gels. The protein was folded to the PrP native conformation by dialysis
against 20 mM sodium acetate buffer, pH= 5. Aggregated material was removed
by centrifugation. Correct folding was confirmed by CD and protein concentration,
by measurement of absorbance at 280 nm. The protein was concentrated using
Amicon centrifugal devices and the concentrated solution stored at −80 °C
until used.
Dynamic mass redistribution. The EnSight Multimode Plate Reader (Perkin Elmer)
was used to carry out DMR analyses. Immobilization of full-length (residues
23–230) or mouse N-terminally truncated (111–230) recombinant PrP (15 μL/well
of a 2.5 μM PrP solution in 10 mM sodium acetate buffer, pH 5) on label-free
microplates (EnSpire-LFB high sensitivity microplates, Perkin Elmer) was obtained
by amine-coupling chemistry. The interaction between Fe3+-TMPyP, SM875 and
SM940 diluted to different concentrations (0.03–100 μM, eight 1:3 serial dilutions)
in assay buffer (10 mM NaHPO3, pH 7.5, 2.4 mM KCl, 138 mM NaCl, 0.05%
Tween-20) and PrP, was monitored after a 30 min incubation at RT. All the steps
were executed by employing a Zephyr Compact Liquid Handling Workstation
(Perkin Elmer). Data were obtained by normalizing each signal on the intra-well
empty surface, and then by subtraction of the control wells. The Kaleido software
(Perkin Elmer) was employed to acquire and process the data.
Temperature-dependent detergent insolubility assay. An 800 μM stock solution of
freshly purified mouse recombinant PrP (residues 111–231) was diluted 1:10 in
sodium acetate (10 mM NaAc, pH 7) to obtain 80 μM aliquots. To avoid pre-
cipitation of recombinant PrP, aliquots were flash frozen in liquid nitrogen, stored
at −80 °C, and then kept on ice during their use. In order to carry out the assay,
recombinant PrP was diluted to a final concentration of 0.5 μM in precipitation
buffer (10 mM NaAc, 2% TX100, pH 7), split in eight identical aliquots, and
incubated for 1 h at different temperatures (25, 37, 45, and 55 °C), in the presence
or absence of each molecule, or vehicle control (0.1% DMSO, volume equivalent).
Each sample was then carefully loaded onto a double layer of sucrose (60% and
80%) prepared in precipitation buffer and deposited at the bottom of ultra-
centrifuge tubes. Samples were then subjected to ultracentrifugation at 100,000 × g
for 1 h at 4 °C. The obtained protein pellets were diluted in 2× LMSB and then
analyzed by western blotting.
Scanning electron microscopy. SM875 (250 μM) was added to an 0.55 mL aliquot of
recombinant PrP (250 μM in 20mM PBS, pH= 6) and the solution was incubated
for 1 h at 55 °C. Upon removal of supernatants, precipitates were collected by
gentle resuspension, transferred to a vial and vigorously vortexed. A 10 μL aliquot
was deposited on a glow-discharged gold-carbon grid. The grid was washed twice
with d.i. water and stained for 1 min with a filtered, freshly prepared solution of 2%
uranyl acetate. Samples were visualized using a ZEISS UltraPlus analytical FESEM
with a grid stage set at 20 kV. For samples subjected to sonication, the same
protocol was employed, with the exception of a short tip-sonication step (5 s, three
times) before depositing the samples on the grid.
Detection of prions in L929 fibroblasts. L929 fibroblasts were grown in culturing
medium and passaged 5–7 times after infection with a 0.5% homogenate of RML
prion strain (corresponding to ∼105 lethal dose at 50%, derived from corre-
sponding prion-infected mice; courtesy of Dr. Roberto Chiesa, Mario Negri
Institute, Milan). In order to test the anti-prion effects of compounds, cells were
seeded in 24-well plates (day 1) at ~60% confluence, with different concentrations
of each molecule, or vehicle control (0.1% DMSO, volume equivalent). Medium
containing fresh compounds or vehicle was replaced on day 2, and cells were split
(1:2) on day 3, avoiding the use of trypsin by pipetting directly onto the well
surface. Cells were collected on day 4 in PBS and centrifuged at 3500 rpm × 3min.
The resulting pellets were then rapidly stored at −80 °C. To evaluate prion loads,
cell pellets were resuspended in 20 μL of lysis buffer (Tris 10 mM, pH 7.4, 0.5% NP-
40, 0.5% TX-100, 150 mM NaCl) and incubated for 10 min at 37 °C with 2000
units/mL of DNase I (New England BioLabs). Half of the resulting sample was
incubated with 10 μg/mL of PK (Sigma Aldrich) for 1 h at 37 °C, whereas the other
half was incubated in the same conditions in the absence of PK. Both PK-treated
and untreated samples were then mixed 1:2 with 4× Laemmli sample buffer (Bio-
Rad) containing DTT, boiled for 8 min at 95 °C and ran by SDS-PAGE. The final
quantification of PK-resistant PrP species was obtained by densitometric analysis
of the western blots, normalizing each signal on the corresponding PK-
untreated lane.
Crystallization. Recombinant mouse PrP (residues 111–230, 800 μM) was heated to
45 °C and slowly cooled to 20 °C using a thermal cycler, either in the presence or
absence of SM875 (2 mM). Massive precipitation was observed in the presence of
SM875. Pellet was removed by centrifugation and a 40% reduction in PrP con-
centration was estimated by UV absorbance at 280 nm. Showers of very thin
needles appeared in 2–4 days (0.2 M (NH4)2SO4, 10 mM CdCl2, 9–14% LMW PEG
smear, 9–14% MMW PEG smear, pH 6–8) irrespectively of whether the protein
was incubated with SM875 or not. Data collection was performed at the Elettra
synchrotron, XRD1 beamline (Trieste, Italy). Crystals were weakly and aniso-
tropically diffracting to 3.7 Å in the best directions. Multiple diffraction patterns
were present, as single needles were impossible to isolate. Orthorhombic crystal
system and unit cell dimensions could be identified (a= 36.1 Å, b= 51.8 Å, c=
55.9 Å), which are extremely similar to those reported for apo human PrP in PDB
3HAK (a= 32.5 Å, b= 49.1 Å, c= 56.9 Å).
Statistics and reproducibility. All the data were collected and analyzed blindly by
two different operators. Uncropped blot images of main figures are reported in
Fig. S16. All source data underlying the graphs and charts presented in the main
figures are available on Figshare (https://doi.org/10.6084/m9.figshare.13299209.v1).
Statistical analyses, performed with the Prism software version 7.0 (GraphPad),
included all the data points obtained, with the exception of experiments in which
negative and/or positive controls did not give the expected outcome, which were
discarded. No test for outliers was employed. The Kolmogorov–Smirnov normality
test was applied (when possible, n ≥ 5). Results were expressed as the mean ±
standard errors, unless specified. In some case, the dose–response experiments
were fitted with a four-parameter logistic (4PL) non-linear regression model, and
Table 1 Primers employed to amplify endogenous and transgenic PrP.
Primer Forward sequence 5′–3′ Reverse sequence 5′–3′
Mouse HPRT (endogenous) TCAGACCGCTTTTTGCCGCGA ATCGCTAATCACGACGCTGGGAC
Mouse PrP set 1 (endogenous) GGACATCACCAAGACGAGGG CGCCATGATGACTGATCCGA
Mouse PrP set 2 (transfected) GCTGGCCCTCTTTGTGACTA GTTCCACCCTCCAGGCTTTG
Human HPRT (endogenous) CAGCCCTGGCGTCGTGATTAGTGA TCACATCTCGAGCAAGACGTTCAGT
Human PrP (endogenous) CCGAGGCAGAGCAGTCATTA CCAGGTCACTCCATGTGGC
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fitting was estimated by calculating the R2. All the data were analyzed with the one-
way analysis of variance test, including an assessment of the normality of data, and
corrected by the Dunnet post-hoc test. Probability (p) values < 0.05 were con-
sidered as significant (*<0.05, **<0.01, ***<0.001).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All the data that support the findings of this study are available within the manuscript,
supplementary files, or from the corresponding authors upon reasonable request. All
source data underlying the graphs and charts presented in the main figures are available
on Figshare (https://doi.org/10.6084/m9.figshare.13299209.v1).
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